MCID: CLN015
MIFTS: 53

Colon Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Colon Adenocarcinoma

MalaCards integrated aliases for Colon Adenocarcinoma:

Name: Colon Adenocarcinoma 12 13 55 15
Adenocarcinoma of the Colon 12 6
Adenocarcinoma of Colon 12 73
Colonic Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:234
NCIt 50 C4349
SNOMED-CT 68 255082000
UMLS 73 C0338106

Summaries for Colon Adenocarcinoma

Disease Ontology : 12 A colon carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colon Adenocarcinoma, also known as adenocarcinoma of the colon, is related to adenocarcinoma and adenoma. An important gene associated with Colon Adenocarcinoma is RAD54L (RAD54 Like), and among its related pathways/superpathways are Endometrial cancer and Development HGF signaling pathway. The drugs Benzocaine and Zinc have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and lung, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Wikipedia : 76 Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from... more...

Related Diseases for Colon Adenocarcinoma

Diseases related to Colon Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 31.9 CDH1 CTNNB1 MLH1 PTGS2
2 adenoma 30.4 CTNNB1 MLH1 ODC1 PTGS2
3 signet ring cell adenocarcinoma 30.3 CDH1 CTNNB1 KRT20
4 colitis 29.9 ABCB1 CTNNB1 MLH1 PTGS2
5 lung cancer susceptibility 3 29.5 CASP3 CDH1 CEACAM5 CTNNB1 KRT20 PTGS2
6 cholangiocarcinoma 29.4 CASP3 CDH1 CEACAM5 CTNNB1 KRT20 PTGS2
7 gastric cancer 28.3 CDH1 CEACAM5 CTNNB1 MLH1 SNHG6
8 hepatocellular carcinoma 28.1 BAX CASP3 CDH1 CEACAM5 CTNNB1 NQO1
9 gastric adenocarcinoma 27.6 BAX CASP3 CDH1 CEACAM5 CTNNB1 KRT20
10 breast cancer 27.0 ABCB1 BAX CASP3 CDH1 CEACAM5 CTNNB1
11 keratosis palmoplantaris adenocarcinoma of the colon 12.1
12 submucosal invasive colon adenocarcinoma 12.0
13 colon mucinous adenocarcinoma 11.1
14 gastrointestinal carcinoma 10.8 ABCB1 KRT20 TYMS
15 linitis plastica 10.8 CDH1 KRT20
16 polyposis syndrome, hereditary mixed, 1 10.8 MLH1 PTGS2
17 lung acinar adenocarcinoma 10.8 CTNNB1 KRT20
18 lower lip cancer 10.8 CASP3 MLH1
19 adenoid squamous cell carcinoma 10.8 CDH1 KRT20
20 esophageal adenosquamous carcinoma 10.7 CDH1 CEACAM5
21 bile duct carcinoma 10.7 CDH1 KRT20 PTGS2
22 ovarian mucinous adenocarcinoma 10.7 ABCB1 KRT20
23 morpheaform basal cell carcinoma 10.7 CDH1 KRT20
24 oral cancer 10.7 CASP3 CDH1 PTGS2
25 atypical polypoid adenomyoma 10.7 CTNNB1 MLH1
26 large intestine adenocarcinoma 10.6 CDH1 CTNNB1 KRT20
27 skin benign neoplasm 10.6 KRT20 MLH1 ODC1
28 goblet cell carcinoid 10.6 CDH1 CTNNB1 KRT20
29 vulval paget's disease 10.6 CEACAM5 KRT20
30 integumentary system cancer 10.6 CEACAM5 KRT20 PTGS2
31 bile duct cystadenocarcinoma 10.6 CEACAM5 KRT20
32 hepatoblastoma 10.6 ABCB1 CASP3 CTNNB1
33 lymphoma, non-hodgkin, familial 10.6 ABCB1 BAX CASP3 RAD54L
34 anaplastic thyroid cancer 10.6 CASP3 CDH1 CTNNB1
35 breast ductal carcinoma 10.6 CDH1 CTNNB1 RAD54L
36 transitional cell carcinoma 10.6 CDH1 KRT20 PTGS2
37 gastric signet ring cell adenocarcinoma 10.6 CDH1 CEACAM5
38 infiltrative basal cell carcinoma 10.6 CDH1 CEACAM5 KRT20
39 colonic benign neoplasm 10.6 CEACAM5 CTNNB1 PTGS2
40 mesothelioma, malignant 10.6 CDH1 CTNNB1 KRT20
41 uterine carcinosarcoma 10.6 CDH1 CTNNB1 PTGS2
42 tongue squamous cell carcinoma 10.5 CASP3 CDH1 CTNNB1
43 barrett esophagus 10.5 CDH1 KRT20 ODC1 PTGS2
44 microinvasive gastric cancer 10.5 CDH1 CEACAM5 MLH1
45 thymus adenocarcinoma 10.5 CEACAM5 KRT20
46 gastric diffuse adenocarcinoma 10.4 CDH1 KRT20
47 cell type benign neoplasm 10.4 CEACAM5 CTNNB1 MLH1
48 endocrine gland cancer 10.4 CDH1 CEACAM5 MLH1
49 colorectal adenoma 10.4 CTNNB1 MLH1 ODC1 PTGS2
50 bladder urothelial carcinoma 10.4 CASP3 CDH1 CTNNB1 KRT20

Graphical network of the top 20 diseases related to Colon Adenocarcinoma:



Diseases related to Colon Adenocarcinoma

Symptoms & Phenotypes for Colon Adenocarcinoma

MGI Mouse Phenotypes related to Colon Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.76 ABCB1 CASP3 CDH1 CTNNB1 CTNND1 MLH1
2 endocrine/exocrine gland MP:0005379 9.61 ABCB1 ACSL4 BAX CASP3 CDH1 CTNNB1
3 neoplasm MP:0002006 9.17 BAX CDH1 CTNNB1 CTNND1 MLH1 NQO1

Drugs & Therapeutics for Colon Adenocarcinoma

Drugs for Colon Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 213)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
2
Zinc Approved, Investigational Phase 4 7440-66-6 23994
3 tannic acid Approved, Nutraceutical Phase 4
4 Hypoglycemic Agents Phase 4
5 insulin Phase 4
6 Insulin, Globin Zinc Phase 4
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
8
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
9
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
10
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
11
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
12
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
13
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
14
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
15
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
16
Raltitrexed Approved, Investigational Phase 3,Phase 2 112887-68-0 104758
17
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
18
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
19
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
20
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
21
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
22
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
23
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
24
Floxuridine Approved Phase 3,Phase 2,Phase 1 50-91-9 5790
25
Dalteparin Approved Phase 3 9005-49-6
26
Tinzaparin Approved Phase 3 9005-49-6, 9041-08-1 25244225
27
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
28
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
29
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
30
Promethazine Approved, Investigational Phase 3 60-87-7 4927
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
32
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
33
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
34
Doxil Approved June 1999 Phase 3,Phase 2 31703
35
Vatalanib Investigational Phase 3 212141-54-3 151194
36
Eniluracil Investigational Phase 3 59989-18-3
37 Alkylating Agents Phase 3,Phase 2,Phase 1
38 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
39 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
40 Anti-Bacterial Agents Phase 3,Phase 2
41 Antibiotics, Antitubercular Phase 3,Phase 2
42 Antidotes Phase 3,Phase 2,Phase 1
43 Antimetabolites Phase 3,Phase 2,Phase 1
44 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
45 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
46 Calcium, Dietary Phase 3,Phase 2,Phase 1,Not Applicable
47 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
48 Micronutrients Phase 3,Phase 2,Phase 1,Early Phase 1
49 Mitomycins Phase 3,Phase 2
50 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 260)
# Name Status NCT ID Phase Drugs
1 Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial Not yet recruiting NCT02746432 Phase 4 Hyper insulinemic euglycemic clamp
2 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
3 Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Unknown status NCT00091312 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
4 Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer Unknown status NCT00005979 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
5 Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00182715 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
6 Combination Chemotherapy in Treating Patients With Colon Cancer Unknown status NCT00046995 Phase 3 carboplatin;fluorouracil;leucovorin calcium
7 Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00070213 Phase 3 FOLFOX regimen;capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
8 Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil Unknown status NCT00389870 Phase 3 cyclosporine;irinotecan hydrochloride
9 Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Unknown status NCT00274872 Phase 2, Phase 3 fluorouracil;leucovorin calcium;oxaliplatin
10 Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer Unknown status NCT00003260 Phase 3 FOLFIRI regimen;FOLFOX regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
11 Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00021281 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;semaxanib
12 Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00008281 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
13 Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00006468 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
14 Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer Unknown status NCT00482222 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
15 Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver Unknown status NCT00002692 Phase 3 fluorouracil;isolated perfusion;leucovorin calcium
16 Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer Unknown status NCT00002893 Phase 3 fluorouracil;leucovorin calcium;raltitrexed
17 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
18 Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery Completed NCT00427310 Phase 3 fluorouracil;sodium heparin
19 Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver Completed NCT00023868 Phase 3 FOLFIRI regimen;cisplatin;doxorubicin hydrochloride;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C
20 Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00003594 Phase 3 irinotecan;fluorouracil;leucovorin calcium;oxaliplatin
21 Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer Completed NCT00056446 Phase 3 Vatalanib
22 Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. Completed NCT00056459 Phase 3 Vatalanib
23 Combination Chemotherapy in Treating Patients With Stage III Colon Cancer Completed NCT00003835 Phase 3 leucovorin calcium;fluorouracil;irinotecan hydrochloride
24 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed NCT00079274 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil;Locally Directed Therapy
25 Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery Completed NCT00660894 Phase 3 folinate calcium;tegafur-uracil;tegafur-gimeracil-oteracil potassium
26 Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon Completed NCT00085163 Phase 3 celecoxib;fluorouracil;leucovorin calcium
27 Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery Completed NCT00265811 Phase 3 Folfox + Cetuximab;Folfox
28 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
29 Combination Chemotherapy in Treating Patients With Resected Colon Cancer Completed NCT00378716 Phase 3 5-fluorouracil;leucovorin calcium;tegafur;uracil
30 Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer Completed NCT00064181 Phase 3 FOLFIRI regimen;capecitabine;celecoxib;fluorouracil;irinotecan hydrochloride;leucovorin calcium
31 Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery Completed NCT00392899 Phase 3 UFT adjuvant chemotherapy
32 Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer Completed NCT00026273 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
33 Laparoscopic-Assisted Surgery Compared With Open Surgery in Treating Patients With Colon Cancer Completed NCT00002575 Phase 3
34 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
35 Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer Completed NCT00003873 Phase 3 fluorouracil;eniluracil
36 Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases Completed NCT00268398 Phase 3 oxaliplatin, folinic acid, fluorouracil;oxaliplatin, irinotecan, folinic acid, fluorouracil
37 Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM) Completed NCT00265824 Phase 3 bevacizumab;bevacizumab, erlotinib
38 Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Completed NCT00004252 Phase 3 fluorouracil;leucovorin calcium;semaxanib
39 Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer Completed NCT00096278 Phase 3 oxaliplatin;leucovorin calcium;fluorouracil
40 Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated Completed NCT00025337 Phase 3 oxaliplatin;leucovorin calcium;fluorouracil
41 Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer Completed NCT00062426 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
42 Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Completed NCT00303771 Phase 3 fluorouracil;irinotecan hydrochloride;leucovorin calcium
43 PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study Completed NCT00911170 Phase 3 Pegfilgrastim;Placebo;Standard Chemotherapy
44 Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer Completed NCT00004885 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
45 Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer Completed NCT00003287 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
46 Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer Completed NCT00008060 Phase 3 FOLFIRI regimen;FOLFOX regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
47 Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer Completed NCT00975897 Phase 2, Phase 3 fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
48 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery Completed NCT00316914 Phase 3 calcium gluconate;magnesium sulfate
49 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Completed NCT01099449 Phase 3 calcium gluconate;magnesium sulfate;oxaliplatin
50 Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Completed NCT00002716 Phase 3 dexamethasone;floxuridine;fluorouracil;leucovorin calcium

Search NIH Clinical Center for Colon Adenocarcinoma

Genetic Tests for Colon Adenocarcinoma

Anatomical Context for Colon Adenocarcinoma

MalaCards organs/tissues related to Colon Adenocarcinoma:

41
Colon, Liver, Lung, Testes, Endothelial, Lymph Node, Thyroid

Publications for Colon Adenocarcinoma

Articles related to Colon Adenocarcinoma:

(show top 50) (show all 830)
# Title Authors Year
1
miR-223-RhoB signaling pathway regulates the proliferation and apoptosis of colon adenocarcinoma. ( 29660302 )
2018
2
Hsa-miR-370 inhibited P-selectin-induced cell adhesion in human colon adenocarcinoma cells. ( 29922946 )
2018
3
Minimally invasive surgery for stage III colon adenocarcinoma is associated with less delay to initiation of adjuvant systemic therapy and improved survival. ( 29967992 )
2018
4
Transforming Growth Factor Beta 2 Inhibits Growth and Proliferation Potential of Smad4 and p53 Mutated Human Colon Adenocarcinoma Cells. ( 29948613 )
2018
5
A rare case of ascending colon adenocarcinoma incarcerated in an inguinoscrotal hernia: case report and literature review. ( 29785528 )
2018
6
Vaccination with human amniotic epithelial cells confer effective protection in a murine model of Colon adenocarcinoma. ( 29139122 )
2018
7
Expression of Hippo pathway genes and their clinical significance in colon adenocarcinoma. ( 29541248 )
2018
8
<i>De novo</i> expression of human polypeptide<i>N</i>-acetylgalactosaminyltransferase 6 (GalNAc-T6) in colon adenocarcinoma inhibits the differentiation of colonic epithelium. ( 29187600 )
2018
9
Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via mitochondrial pathway and PI3K/AKT/mTOR inactivation. ( 29289836 )
2018
10
Curcumin induces apoptosis and cell cycle arrest via the activation of reactive oxygen species-independent mitochondrial apoptotic pathway in Smad4 and p53 mutated colon adenocarcinoma HT29 cells. ( 29673545 )
2018
11
A rare case of oral metastasis of colon adenocarcinoma. ( 29475082 )
2018
12
G protein-coupled receptor LGR6 is an independent risk factor for colon adenocarcinoma. ( 29971639 )
2018
13
Comprehensive analysis of differential expression profiles of mRNAs and lncRNAs and identification of a 14-lncRNA prognostic signature for patients with colon adenocarcinoma. ( 29565464 )
2018
14
Colon adenocarcinoma presenting a Plummer-Vinson Syndrome. ( 29885869 )
2018
15
Co-expression Network Analysis Identified COL8A1 Is Associated with the Progression and Prognosis in Human Colon Adenocarcinoma. ( 29497907 )
2018
16
Phalangeal metastasis in colon adenocarcinoma. ( 29807858 )
2018
17
A 65a89gene signature for prognostic prediction in colon adenocarcinoma. ( 29393333 )
2018
18
A rare case of <i>Clostridium septicum</i> aortitis with colon adenocarcinoma. ( 29707691 )
2018
19
Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. ( 29454261 )
2018
20
18F-FDG PET/CT of Seminal Vesicle Metastasis From Ascending Colon Adenocarcinoma. ( 28005644 )
2017
21
Effect of normalization methods on the performance of supervised learning algorithms applied to HTSeq-FPKM-UQ data sets: 7SK RNA expression as a predictor of survival in patients with colon adenocarcinoma. ( 29112707 )
2017
22
A microRNA expression signature as a predictor of survival for colon adenocarcinoma. ( 27881005 )
2017
23
Significance of histone methyltransferase SETDB1 expression in colon adenocarcinoma. ( 28913972 )
2017
24
Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study. ( 28850633 )
2017
25
PPA1 regulates tumor malignant potential and clinical outcome of colon adenocarcinoma through JNK pathways. ( 28938583 )
2017
26
ANTIOXIDANT potential of Cheddar cheeses to tackle human colon adenocarcinoma (Caco-2) cells. ( 28728356 )
2017
27
Inhibition of TRPM7 suppresses cell proliferation of colon adenocarcinoma in vitro and induces hypomagnesemia in vivo without affecting azoxymethane-induced early colon cancer in mice. ( 28810912 )
2017
28
Prognostic significance of high YY1AP1 and PCNA expression in colon adenocarcinoma. ( 29037809 )
2017
29
Colon adenocarcinoma after jejunoileal bypass for morbid obesity. ( 29230281 )
2017
30
High association of Cryptosporidium spp. infection with colon adenocarcinoma in Lebanese patients. ( 29261714 )
2017
31
Induction of Apoptosis and Cell Cycle Arrest by Flavokawain C on HT-29 Human Colon Adenocarcinoma via Enhancement of Reactive Oxygen Species Generation, Upregulation of p21, p27, and GADD153, and Inactivation of Inhibitor of Apoptosis Proteins. ( 28808400 )
2017
32
Improved efficacy of hyperthermia by auraptene in human colon adenocarcinoma cells. ( 28915362 )
2017
33
A case of sigmoid colon adenocarcinoma diagnosed as facial cutaneous metastasis for survival after operation for 37A months. ( 28776316 )
2017
34
The Relationship Between Cytokeratins 7 and 20 Expression, and Prognostic Factors in Colon Adenocarcinoma: An Immunohistochemical Study. ( 29515629 )
2017
35
Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma. ( 28811946 )
2017
36
Rutamarin, an Active Constituent from Ruta angustifolia Pers., Induced Apoptotic Cell Death in the HT29 Colon Adenocarcinoma Cell Line. ( 28808378 )
2017
37
Binase Immobilized on Halloysite Nanotubes Exerts Enhanced Cytotoxicity toward Human Colon Adenocarcinoma Cells. ( 28955235 )
2017
38
Thyroid Metastasis as First Manifestation of a Colon Adenocarcinoma With KRAS Mutation: Usefulness of 18F-FDG PET/CT. ( 28872477 )
2017
39
Bioinformatics analysis of RNA-seq data revealed critical genes in colon adenocarcinoma. ( 28742206 )
2017
40
Tetrac-conjugated polymersomes for integrin-targeted delivery of camptothecin to colon adenocarcinoma in vitro and in vivo. ( 28935257 )
2017
41
Curcumin inhibits growth potential by G1 cell cycle arrest and induces apoptosis in p53-mutated COLO 320DM human colon adenocarcinoma cells. ( 28011386 )
2017
42
Thyroid Metastasis as First Manifestation of a Colon Adenocarcinoma With KRAS Mutation: Usefulness of 18F-FDG PET/CT. ( 28759522 )
2017
43
Homeodomain Protein Transforming Growth Factor Beta-Induced Factor 2 Like, X-Linked Function in Colon Adenocarcinoma Cells ( 28843229 )
2017
44
Metastatic colon adenocarcinoma has a significantly elevated expression of IL-10 compared to primary colon adenocarcinoma tumors. ( 28812429 )
2017
45
Sclerosing mesenteritis mimicking metachronous peritoneal metastases from descending colon adenocarcinoma. ( 28764712 )
2017
46
Mertensene, a Halogenated Monoterpene, Induces G2/M Cell Cycle Arrest and Caspase Dependent Apoptosis of Human Colon Adenocarcinoma HT29 Cell Line through the Modulation of ERK-1/-2, AKT and NF-I_B Signaling. ( 28726723 )
2017
47
A long non-coding RNA expression signature to predict survival of patients with colon adenocarcinoma. ( 29254165 )
2017
48
Risk Factors in the Management of Repeated Lung Resection for Colon Adenocarcinoma Metastasectomy. ( 29153794 )
2017
49
Characterization of Cancer Stem Cells in Colon Adenocarcinoma Metastasis to the Liver. ( 29404335 )
2017
50
MicroRNA-1254 inhibits the migration of colon adenocarcinoma cells by targeting PSMD10. ( 28296190 )
2017

Variations for Colon Adenocarcinoma

ClinVar genetic disease variations for Colon Adenocarcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 RAD54L NM_001142548.1(RAD54L): c.188C> A (p.Pro63His) single nucleotide variant Pathogenic rs121908688 GRCh37 Chromosome 1, 46715769: 46715769
2 RAD54L NM_001142548.1(RAD54L): c.188C> A (p.Pro63His) single nucleotide variant Pathogenic rs121908688 GRCh38 Chromosome 1, 46250097: 46250097

Cosmic variations for Colon Adenocarcinoma:

9
(show top 50) (show all 11135)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM33066 ZZZ3 large intestine,colon,carcinoma,NS c.1366C>T p.P456S 1:77631989-77631989 9
2 COSM6940205 ZRSR2 large intestine,colon,carcinoma,NS c.553G>T p.D185Y 23:15809314-15809314 9
3 COSM6452015 ZRSR2 large intestine,colon,carcinoma,NS c.917G>A p.R306Q 23:15820296-15820296 9
4 COSM33067 ZNHIT6 large intestine,colon,carcinoma,NS c.1364T>A p.L455H 1:85657855-85657855 9
5 COSM32824 ZNHIT1 large intestine,colon,carcinoma,NS c.400C>T p.R134W 7:101223799-101223799 9
6 COSM50818 ZNF813 large intestine,colon,carcinoma,NS c.1636G>A p.G546R 19:53491871-53491871 9
7 COSM50465 ZNF536 large intestine,colon,carcinoma,NS c.1158G>T p.W386C 19:30444720-30444720 9
8 COSM50466 ZNF536 large intestine,colon,carcinoma,NS c.2533C>G p.L845V 19:30548152-30548152 9
9 COSM50281 ZNF521 large intestine,colon,carcinoma,NS c.3524C>T p.T1175M 18:25224394-25224394 9
10 COSM50969 ZNF280D large intestine,colon,carcinoma,NS c.2020A>C p.R674R 15:56658461-56658461 9
11 COSM32994 ZNF217 large intestine,colon,carcinoma,NS c.967G>A p.D323N 20:53581860-53581860 9
12 COSM32679 ZNF155 large intestine,colon,carcinoma,NS c.1421A>G p.H474R 19:43997278-43997278 9
13 COSM50671 ZMIZ2 large intestine,colon,carcinoma,NS c.1850G>A p.R617H 7:44763403-44763403 9
14 COSM50764 ZFHX4 large intestine,colon,carcinoma,NS c.681C>A p.F227L 8:76704769-76704769 9
15 COSM6964399 ZFHX3 large intestine,colon,carcinoma,NS c.2339C>T p.A780V 16:72957807-72957807 9
16 COSM6944275 ZFHX3 large intestine,colon,carcinoma,NS c.2324C>T p.A775V 16:72957822-72957822 9
17 COSM6957094 ZFHX3 large intestine,colon,carcinoma,NS c.3412A>T p.I1138F 16:72889767-72889767 9
18 COSM6953704 ZFHX3 large intestine,colon,carcinoma,NS c.1623G>C p.Q541H 16:72958523-72958523 9
19 COSM6845173 ZFHX3 large intestine,colon,carcinoma,NS c.3863C>T p.T1288M 16:72811578-72811578 9
20 COSM973505 ZFHX3 large intestine,colon,carcinoma,NS c.7928G>A p.R2643H 16:72794754-72794754 9
21 COSM6964664 ZFHX3 large intestine,colon,carcinoma,NS c.2318C>T p.A773V 16:72957828-72957828 9
22 COSM6939325 ZFHX3 large intestine,colon,carcinoma,NS c.9997C>A p.Q3333K 16:72788279-72788279 9
23 COSM6845177 ZFHX3 large intestine,colon,carcinoma,NS c.7490C>T p.S2497L 16:72795192-72795192 9
24 COSM6941798 ZFHX3 large intestine,colon,carcinoma,NS c.10754C>G p.S3585C 16:72787522-72787522 9
25 COSM6941382 ZFHX3 large intestine,colon,carcinoma,NS c.392G>T p.G131V 16:72959754-72959754 9
26 COSM6964606 ZFHX3 large intestine,colon,carcinoma,NS c.5555A>C p.Q1852P 16:72797127-72797127 9
27 COSM6939326 ZFHX3 large intestine,colon,carcinoma,NS c.4242A>C p.E1414D 16:72798440-72798440 9
28 COSM6964400 ZFHX3 large intestine,colon,carcinoma,NS c.500C>T p.P167L 16:72959646-72959646 9
29 COSM6941989 ZFHX3 large intestine,colon,carcinoma,NS c.4251G>C p.Q1417H 16:72798431-72798431 9
30 COSM6941490 ZFHX3 large intestine,colon,carcinoma,NS c.10415C>T p.A3472V 16:72787861-72787861 9
31 COSM6955210 ZFHX3 large intestine,colon,carcinoma,NS c.7381G>A p.E2461K 16:72795301-72795301 9
32 COSM4062694 ZFHX3 large intestine,colon,carcinoma,NS c.10346C>T p.A3449V 16:72787930-72787930 9
33 COSM6955208 ZFHX3 large intestine,colon,carcinoma,NS c.7804A>G p.T2602A 16:72794878-72794878 9
34 COSM6942790 ZFHX3 large intestine,colon,carcinoma,NS c.1532C>A p.P511H 16:72958614-72958614 9
35 COSM6977044 ZFHX3 large intestine,colon,carcinoma,NS c.3367C>T p.R1123W 16:72889812-72889812 9
36 COSM6956224 ZFHX3 large intestine,colon,carcinoma,NS c.950T>A p.L317H 16:72959196-72959196 9
37 COSM6941990 ZFHX3 large intestine,colon,carcinoma,NS c.1081G>A p.G361R 16:72959065-72959065 9
38 COSM6978946 ZFHX3 large intestine,colon,carcinoma,NS c.9227T>G p.M3076R 16:72793455-72793455 9
39 COSM6927022 ZFHX3 large intestine,colon,carcinoma,NS c.2822C>T p.S941L 16:72950863-72950863 9
40 COSM6959968 ZFHX3 large intestine,colon,carcinoma,NS c.2548C>A p.L850I 16:72957598-72957598 9
41 COSM6950051 ZFHX3 large intestine,colon,carcinoma,NS c.1238C>A p.T413N 16:72958908-72958908 9
42 COSM4062703 ZFHX3 large intestine,colon,carcinoma,NS c.8968G>A p.V2990I 16:72793714-72793714 9
43 COSM6974762 ZFHX3 large intestine,colon,carcinoma,NS c.9467G>A p.S3156N 16:72788809-72788809 9
44 COSM3276831 ZFHX3 large intestine,colon,carcinoma,NS c.6296C>T p.P2099L 16:72796386-72796386 9
45 COSM6845159 ZFHX3 large intestine,colon,carcinoma,NS c.3829G>A p.V1277M 16:72811612-72811612 9
46 COSM6955209 ZFHX3 large intestine,colon,carcinoma,NS c.7666G>A p.A2556T 16:72795016-72795016 9
47 COSM33074 ZEB2 large intestine,colon,carcinoma,NS c.2947G>A p.D983N 2:144396532-144396532 9
48 COSM32424 ZDHHC7 large intestine,colon,carcinoma,NS c.130G>A p.D44N 16:84990489-84990489 9
49 COSM32851 ZBTB46 large intestine,colon,carcinoma,NS c.25G>T p.E9* 20:63790733-63790733 9
50 COSM33142 YIPF1 large intestine,colon,carcinoma,NS c.475C>T p.R159* 1:53871378-53871378 9

Expression for Colon Adenocarcinoma

Search GEO for disease gene expression data for Colon Adenocarcinoma.

Pathways for Colon Adenocarcinoma

Pathways related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.73 BAX CASP3 CDH1 CTNNB1 MLH1
2
Show member pathways
12.55 BAX CASP3 CDH1 CTNNB1 PTGS2
3
Show member pathways
12.47 ABCB1 BAX CDH1 CTNNB1 MLH1 NQO1
4 12.42 BAX CASP3 CDH1 CTNNB1 MLH1 NQO1
5 11.79 CDH1 CEACAM5 CTNNB1 CTNND1
6 11.73 BAX CASP3 PTGS2
7
Show member pathways
11.72 CDH1 CTNNB1 CTNND1
8 11.65 BAX CASP3 CDH1 CTNNB1 MLH1 PTGS2
9 11.59 BAX CASP3 MLH1
10 11.57 CDH1 CTNNB1 CTNND1
11 11.45 CASP3 CTNNB1 PTGS2
12 11.31 CDH1 CTNNB1 CTNND1
13 11.29 BAX CASP3 CDH1 CTNNB1 ODC1 RAD54L
14 11.26 CDH1 CTNNB1 CTNND1
15
Show member pathways
11.23 ABCB1 MLH1 NQO1
16 11.21 CDH1 CTNNB1 CTNND1
17 11.06 CDH1 CTNNB1 CTNND1
18 10.79 ABCB1 BAX CASP3
19 10.77 ABCB1 PTGS2
20 10.68 CDH1 CTNNB1
21 10.56 ABCB1 BAX

GO Terms for Colon Adenocarcinoma

Cellular components related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.69 BAX CTNNB1 ODC1
2 response to organic substance GO:0010033 9.67 CASP3 CDH1 PTGS2
3 response to organic cyclic compound GO:0014070 9.67 CASP3 NQO1 PTGS2 TYMS
4 response to glucocorticoid GO:0051384 9.63 CASP3 PTGS2 TYMS
5 response to toxic substance GO:0009636 9.62 BAX CDH1 NQO1 TYMS
6 adherens junction organization GO:0034332 9.58 CDH1 CTNNB1 CTNND1
7 response to estradiol GO:0032355 9.56 CASP3 CTNNB1 NQO1 PTGS2
8 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.48 BAX CASP3
9 cellular response to indole-3-methanol GO:0071681 9.43 CDH1 CTNNB1
10 entry of bacterium into host cell GO:0035635 9.33 CDH1 CTNNB1 CTNND1
11 positive regulation of neuron apoptotic process GO:0043525 9.26 BAX CASP3 CTNNB1 NQO1
12 response to drug GO:0042493 9.17 ABCB1 CASP3 CDH1 CTNNB1 PTGS2 RAD54L

Molecular functions related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.1 BAX CDH1 CEACAM5 ODC1 PTGS2 TYMS

Sources for Colon Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....